

## **PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting**


*Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery*

PETACH TIKVA, Israel, April 28, 2026 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will present at the 45th Annual Meeting of the Surgical Infection Society, taking place on May 5-6, 2026, at the Coronado Island Marriott in Coronado, California. The presentation will focus on a detailed analysis of the ASEPSIS (**A**dditional treatment, **S**erous discharge, **E**rythema, **P**urulent exudate, **S**eparation of deep tissues, **I**solation of bacteria, and prolonged **S**tay as inpatient) score data from the Company’s Phase 3 SHIELD II trial of D-PLEX<sub>100</sub>.

The presentation will be delivered by Dr. Robert G. Sawyer, MD, FSIS, FACS, FCCM, FIDSA, a Professor and Chair of the Department of Surgery at Western Michigan University Homer Stryker M.D. School of Medicine. Dr. Sawyer also serves as Senior Associate Dean for Research and Editor-in-Chief of the journal Surgical Infections.

The ASEPSIS score is a validated, objective clinical scoring system used to assess the severity of surgical wound infections. It integrates parameters such as wound appearance, antibiotic use, drainage of pus, isolation of pathogenic bacteria, and length of hospital stay. As previously reported in the SHIELD II topline results, treatment with D-PLEX<sub>100</sub> together with the standard of care resulted in a 64% relative risk reduction ( $p=0.0103$ ) in the proportion of patients with an ASEPSIS score greater than 20, the threshold indicative of clinically significant wound infection, compared to the standard of care alone.

## Number of patients with ASEPSIS Score >20 (ITT Cohort)



“The ASEPSIS score outcomes demonstrate not only that D-PLEX reduces surgical site infections (“SSI”) events by 60%, but also that those infections that ultimately breakthrough are less severe and less complicated,” said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. “Fewer SSIs, together with fewer high-severity wound infections, translate directly into better outcomes for patients, including fewer wound complications, less reliance on intravenous antibiotics for treatment of infection, and the potential for earlier hospital discharge. Just as importantly, this carries meaningful implications for hospital economics, with reductions in physician and nursing time, antibiotic stewardship resources, and the overall cost burden associated with extended length of stay and management of complicated postoperative infections.”

### ***Surgical Infection Society 2026 Annual Meeting Presentation Details***

**Title:** *Evaluation of ASEPSIS Score as a Secondary Endpoint in the Phase 3 SHIELD II Trial of D-PLEX<sub>100</sub> in Colorectal Surgery*

**Presenter:** Robert G. Sawyer, MD, FSIS, FACS, FCCM, FIDSA, Professor and Chair, Department of Surgery, Western Michigan University Homer Stryker M.D. School of Medicine; Senior Associate Dean for Research; Editor-in-Chief, Surgical Infections

**Session:** Scientific Session III

**Date/Time:** Wednesday, May 6, 2026 | 8:00 a.m. – 9:00 a.m. PT

**Location:** Coronado Island Marriott, Coronado, California

### **About D-PLEX<sub>100</sub>**

D-PLEX<sub>100</sub>, PolyPid’s lead product candidate, is designed to provide local prolonged and

controlled anti-bacterial activity directly at the surgical site to prevent surgical site infections (“SSIs”). Following the administration of D-PLEX<sub>100</sub> into the surgical site, PolyPid’s delivery technology, Kynatrix, pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX<sub>100</sub> recently demonstrated positive results in the Phase 3 SHIELD II trial, achieving a statistically significant 60% ( $p=0.0013$ ) relative risk reduction in SSI incidence following abdominal colorectal surgery with large incisions. D-PLEX<sub>100</sub> received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery.

### **About PolyPid**

PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX<sub>100</sub>, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit <http://www.polypid.com> and follow us on Twitter (X) and LinkedIn.

### **Forward-looking Statements**

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential clinical and economic benefits of D-PLEX<sub>100</sub>, including its potential to reduce the incidence of severe wound infections, decrease wound complications and the use of intravenous antibiotics, enable earlier hospital discharge, and lower hospital resource utilization, and the potential role of D-PLEX<sub>100</sub> in improving the prevention of SSIs. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking

statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed on February 25, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

**Company Contact:**

PolyPid Ltd.  
Ori Warshavsky  
908-858-5995  
IR@Polypid.com

**Investor Relations Contact:**

Arx Investor Relations  
North American Equities Desk  
polypid@arxhq.com

A photo accompanying this announcement is available at  
<https://www.globenewswire.com/NewsRoom/AttachmentNg/43a11cdb-f86b-4d84-bfb0-1870a0a2cb4e>

